BSR DMARD monitoring guidelines: sulfasalazine SIR, Regarding the recommendations for monitoring SSZ, I and my colleagues [1] recently reported a series of patients with serious hepatotoxicity associated with SSZ including two patients with liver failure. Some, but not all, of our patients met the criteria for the DRESS (drug rash with eosinophilia and systemic symptoms) syndrome. This term, we feel, is unnecessarily restrictive and other published descriptors for early toxicity with SSZ include the terms 'three week syndrome' or 'sulphone syndrome'. The purpose of this comment is to highlight that serious and potentially lifethreatening toxicity with SSZ arises within 6 weeks of therapy. Whilst such toxicity is uncommon (we estimated that the frequency of hepatitis with SSZ was 0.4% in our population) it is clear that a recommendation to monitor blood every 4 weeks, according to the new BSR/BHPR guidelines [2] , is likely to lead to a delay in recognizing such toxicity. Our own local guidance recommends testing of blood every 2 weeks for the first 3 months of treatment [3] . Patients are also warned, when being counselled about treatment, to discontinue the drug if they develop a rash or become generally unwell and to seek medical advice. 
